Moderna Stock

Moderna Stock-Based Compensation

The Stock-Based Compensation (SBC) of Moderna (MRNA) as of Aug 20, 2026 is 483.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 429.00 M USD — a change of 12.59% (higher).

Stock-Based Compensation

483.00 MUSD

YoY

12.59%

Last updated:

Stock-Based Compensation (SBC) of Moderna is 2026 483.00 M USD. Stock-Based Compensation (SBC) of Moderna was 2025 429.00 M USD. It decreases by 12.59% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

Stock-Based Compensation (SBC) of Moderna is 483.00 M USD in 2026.

Stock-Based Compensation (SBC) of Moderna changed from 429.00 M USD to 483.00 M USD, representing a 12.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Moderna since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Moderna historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Moderna

All Key Metrics — Moderna